Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Biochem Pharmacol ; 193: 114762, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34499871

RESUMO

The allosteric modulating free fatty acid receptor 2 ligands Cmp58 and AZ1729, increased the activity induced by orthosteric receptor agonists mediating a rise in intracellular calcium ions and activation of the neutrophil NADPH-oxidase. Together, the two modulators triggered an orthosteric-agonist-independent activation of the oxidase without any rise in the concentration of intracellular calcium ions. In this study, structurally diverse compounds presumed to be ligands for free fatty acid receptor 2 were used to gain additional insights into receptor-modulation/signaling. We identified two molecules that activate neutrophils on their own and we classified one as allosteric agonist and the other as orthosteric agonist. Ten compounds were classified as allosteric FFA2R modulators. Of these, one activated neutrophils when combined with AZ1729; the nine remaining compounds activated neutrophils solely when combined with Cmp58. The activation signals were primarily biased when stimulated by two allosteric modulators interacting with different binding sites, such that two complementary modulators together triggered an activation of the NADPH-oxidase but no increase in the intracellular concentration of calcium ions. No neutrophil activation was induced when allosteric receptor modulators suggested to be recognized by the same binding site were combined, results in agreement with our proposed model for activation, in which the receptor has two different sites that selectively bind allosteric modulators. The down-stream signaling mediated by cross-sensitizing allosteric receptor modulators, occurring independent of any orthosteric agonist, represent a new mechanism for activation of the neutrophil NADPH oxidase.


Assuntos
Guanidinas/farmacologia , Isoquinolinas/farmacologia , Neutrófilos/fisiologia , Receptores de Superfície Celular/agonistas , Receptores de Superfície Celular/metabolismo , Cálcio/metabolismo , Descoberta de Drogas , Regulação da Expressão Gênica/efeitos dos fármacos , Guanidinas/química , Humanos , Isoquinolinas/química , Ligantes , Estrutura Molecular , NADPH Oxidases , Relação Estrutura-Atividade
2.
Biochim Biophys Acta Mol Cell Res ; 1867(6): 118689, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32092308

RESUMO

The non-activating allosteric modulator AZ1729, specific for free fatty acid receptor 2 (FFAR2), transfers the orthosteric FFAR2 agonists propionate and the P2Y2R specific agonist ATP into activating ligands that trigger an assembly of the neutrophil superoxide generating NADPH-oxidase. The homologous priming effect on the propionate response and the heterologous receptor cross-talk sensitized ATP response mediated by AZ1729 are functional characteristics shared with Cmp58, another non-activating allosteric FFAR2 modulator. In addition, AZ1729 also turned Cmp58 into a potent activator of the superoxide generating neutrophil NADPH-oxidase, and in agreement with the allosteric modulation concept, the effect was reciprocal in that Cmp58 turned AZ1729 into a potent activating allosteric agonist. The activation signals down-stream of FFAR2 when stimulated by the two interdependent allosteric modulators were biased in that, unlike for orthosteric agonists, the two complementary modulators together triggered an activation of the NADPH-oxidase, but not any transient rise in the cytosolic concentration of free calcium ions (Ca2+). Furthermore, following AZ1729/Cmp58 activation, the signaling by the desensitized FFAR2s was functionally selective in that the orthosteric agonist propionate could still induce a transient rise in intracellular Ca2+. The novel neutrophil activation and receptor down-stream signaling pattern mediated by the two cross-sensitizing allosteric FFAR2 modulators represent a new regulatory mechanism that controls receptor signaling.


Assuntos
Benzamidas/farmacologia , Neutrófilos/metabolismo , Fenilbutiratos/farmacologia , Receptores de Superfície Celular/agonistas , Trifosfato de Adenosina/metabolismo , Regulação Alostérica/efeitos dos fármacos , Benzamidas/química , Cálcio/metabolismo , Sinergismo Farmacológico , Humanos , Estrutura Molecular , NADPH Oxidases/metabolismo , Ativação de Neutrófilo , Neutrófilos/efeitos dos fármacos , Fenilbutiratos/química , Propionatos/metabolismo , Receptores de Superfície Celular/química , Transdução de Sinais/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA